WorldHeart
This article was originally published in The Gray Sheet
Executive Summary
Enhanced version of ePTFE inflow conduit for use with the Novacor LVAS left ventricular assist system is reintroduced in EU countries following European approval, the firm announces April 10. WorldHeart withdrew the product in September 2001 to enhance structural integrity following reports of kinking in recovered devices. WorldHeart also has received go-ahead to recommence its halted NICE study of the conduit in the U.S. and plans to seek FDA approval later this year...
You may also be interested in...
WorldHeart/Edwards Pump Up Novacor As Destination Therapy In Europe
WorldHeart and marketing partner Edwards Lifesciences will promote the Novacor left ventricular assist device (LVAD) as a destination therapy for heart failure patients in Europe following CE mark approval of a package of device enhancements, expected by the end of May
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.